<DOC>
	<DOCNO>NCT00369850</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , bone mineral density test x-ray , help measure bone loss woman receive treatment breast cancer . The test result may help doctor plan good treatment . PURPOSE : This phase III trial study bone density bone loss postmenopausal woman breast cancer receive treatment clinical trial IBCSG-1-98 .</brief_summary>
	<brief_title>Bone Density Bone Loss Postmenopausal Women With Breast Cancer Receiving Treatment Clinical Trial IBCSG-1-98</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect bone mineral density ( BMD ) L2-L4 ( posterio-anterior ) region spine hip assess bone density postmenopausal woman breast cancer receive treatment protocol IBCSG-1-98 . - Compare incidence radiological gross change fracture identify spine x-ray ( T4-L4 ) patient ( group 1 2 ) . - Use longitudinal BMD measurement estimate linear rate bone loss base mixed effect model . - Identify serum marker bone loss determine correlate osteoporosis , microfractures , clinical fracture , breast cancer-related bone event . OUTLINE : This multicenter study substudy protocol IBCSG-1-98 . Patients assign 1 3 group accord length treatment undergone protocol IBCSG-1-98 . - Group 1 ( prior end second year treatment protocol IBCSG-1-98 ) : Patients undergo bone mineral density ( BMD ) test L2-L4 spine hip baseline year 1 , 2 , 3 , 4 baseline . They also undergo x-rays T4-L4 spine baseline year 1 , 3 , 4 baseline . - Group 2 ( 2 year end third year treatment protocol IBCSG-1-98 ) : Patients undergo BMD test L2-L4 spine hip baseline year 1 , 2 , 3 baseline . They also undergo x-rays T4-L4 spine baseline year 2 3 baseline . - Group 3 ( 3 year end fifth year treatment protocol IBCSG-1-98 ) : Patients undergo BMD test L2-L4 spine hip baseline year 1 2 baseline ( patient 4th year treatment ) year 1 baseline ( patient 5th year treatment ) . Patients undergo blood collection baseline periodically study biomarker correlative study . PROJECTED ACCRUAL : A total 660 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Resected disease Enrolled protocol IBCSG198 Receiving adjuvant endocrine therapy comprise 1 follow regimen : Letrozole Tamoxifen Letrozole 2 year tamoxifen Tamoxifen 2 year letrozole Not yet complete 5 year treatment No breast cancer recurrence second primary cancer No known , symptomatic bone disease , include osteomalacia osteogenesis imperfecta No prior registration protocol IBCSG198 Bone Mineral Density substudy Hormone receptor status : Estrogen receptorpositive and/or progesterone receptorpositive tumor PATIENT CHARACTERISTICS : Female Postmenopausal No uncontrolled thyroid parathyroid disease , Cushing 's disease , pituitary diseases No malabsorption syndrome clinically relevant vitamin D deficiency No patient bone density determination impossible PRIOR CONCURRENT THERAPY : See Disease Characteristics More 1 year since prior concurrent anticonvulsant More 6 week since prior concurrent corticosteroid ( dos &gt; equivalent 5 mg/day prednisone ) &gt; 2 week total No prior concurrent sodium fluoride ( daily dose ≥ 5 mg/day ) &gt; 1 month More 12 month since prior concurrent anabolic steroid More 6 month since prior treatment , either investigational , prevention osteoporosis ( exclude calcium cholecalciferol [ vitamin D ] ) No concurrent raloxifene Concurrent therapeutic intervention osteoporosis comprise bisphosphonates allow Concurrent warfarin allow provide give ≤ 4 week</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>